FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:365-366 August 3, 2000 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Alendronate is indicated for the treatment of postmenopausal women with osteoporosis and patients with glucocorticoid-induced osteoporosis.¹ We report liver dysfunction due to alendronate in a postmenopausal woman given the drug for osteoporosis.

A 71-year-old woman was referred to our clinic for an evaluation of osteoporosis. She had been thought to have primary biliary cirrhosis four years earlier, was receiving ursodeoxycholic acid (ursodiol), and had normal liver function. The diagnosis of primary biliary cirrhosis had been based on high serum alkaline phosphatase and antimitochondrial antibody concentrations, but liver biopsy had not been performed.

Three years later, on evaluation . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Haddy, T. B., Mosher, R. B., Reaman, G. H. (2001). Osteoporosis in Survivors of Acute Lymphoblastic Leukemia. The Oncologist 6: 278-285 [Abstract] [Full Text]